Compare YSG & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSG | OBIO |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | China | United States |
| Employees | N/A | 86 |
| Industry | Package Goods/Cosmetics | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.0M | 240.7M |
| IPO Year | 2020 | 2020 |
| Metric | YSG | OBIO |
|---|---|---|
| Price | $3.11 | $4.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.25 |
| AVG Volume (30 Days) | ★ 243.9K | 239.6K |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,482,000.00 |
| Revenue This Year | $23.08 | N/A |
| Revenue Next Year | $9.45 | $12.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $2.15 | $2.20 |
| 52 Week High | $11.04 | $5.42 |
| Indicator | YSG | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.83 | 54.08 |
| Support Level | $2.76 | $4.07 |
| Resistance Level | $3.23 | $4.18 |
| Average True Range (ATR) | 0.39 | 0.17 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 51.34 | 86.49 |
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands. Geographically, company operates in PRC, Europe and US regions.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.